Role of progestins with partial antiandrogenic effects

Climacteric

Volumn 7, Issue 3, 2004, Pages 238-254

  Sitruk Ware, R ^a,h   Husmann, F ^b   Thijssen, J H H ^c   Skouby, S O ^d   Fruzzetti, F ^e   Hanker, J ^b,f,g   Huber, J ^a   Druckmann, R ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b University Medical Center ^*

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF PISA   (Italy)

^f UNIVERSITY OF TRIER   (Germany)

^g University of Venna Medical School   (United States)

^h POPULATION COUNCIL   (United States)

Author keywords

Androgen; Breast; Lipids; Menopause; Metabolic syndrome; Progestin

Indexed keywords

ANTIANDROGEN; C PEPTIDE; CHLORMADINONE ACETATE; CHOLESTEROL; CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; DROSPIRENONE; ELCOMETRINE; ESTRADIOL; ESTRADIOL VALERATE; GESTODENE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LEVONORGESTREL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NANDROLONE; NOMEGESTROL ACETATE; NORETHISTERONE; NORGESTIMATE; NORGESTREL; PROGESTERONE DERIVATIVE; PROMEGESTONE; TRIMEGESTONE; UNINDEXED DRUG;

ANDROGEN BLOOD LEVEL; BREAST; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DRUG EFFECT; HEALTH PROGRAM; HORMONE ACTION; HUMAN; INTERNATIONAL COOPERATION; LIBIDO; MENOPAUSE; PRIORITY JOURNAL; PUBLICATION; WOMEN HEALTH INITIATIVE;

EID: 4944242293     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/13697130400001307     Document Type: Conference Paper

References (104)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33
2. Col NF, Pauker SG. The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience? Ann Intern Med 2003;139:923-9
3. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. a prospective, observational study. Ann Intern Med 2001;135:1-8
4. Burger HG. Androgen production in women. Fertil Steril 2002;77(Suppl 4):S3-S5
5. Longcope C, Hunter R, Franz C. Steroid secretion by the postmenopausal ovary. Am J Obstet Gynecol 1980;138:564-8
6. Honore LH, Chari R, Mueller HD, et al. Postmenopausal hyperandrogenism of ovarian origin. a clinicopathologic study of four cases. Gynecol Obstet Invest 1992;34:52-6
7. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol 1997;11:341-55
8. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404-11
9. Hajamor S, Despres JP, Couillard C, et al. Relationship between sex hormone-binding globulin levels and features of the metabolic syndrome. Metabolism 2003;52:724-30
10. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51:188-215
11. Sitruk-Ware R, Small M. New methods of progestin delivery. Contem Clin Gynecol Obstet 2002;2:287-98
12. Schneider HP. The role of antiandrogens in hormone replacement therapy. Climacteric 2000;3(Suppl 2):21-7
13. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38
14. Oettel M, Graser T, Hoffman H, et al. Why dienogest as a progestogenic component of postmenopausal nonadrenergic hormone replacement therapy? Drugs Today 2001;37:3-15
15. Schindler AE. Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception. Eur J Obstet Gynecol Reprod Biol 2004;112:136-41
16. Duc I, Botella J, Bonnet P, et al. Antiandrogenic properties of nomegestrol acetate. Arzneimittelforschung 1995;45:70-4
17. Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 2003;68:915-20
18. Schneider HP. Androgens and antiandrogens. Ann N Y Acad Sci 2003;997:292-306
19. Kumar N, Koide SS, Tsong Y, et al. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000;65:629-36
20. Philibert D, Bouchoux F, Degryse M, et al. The pharmacological profile of a novel norpregnance progestin (trimegestone). Gynecol Endocrinol 1999;13:316-26
21. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002;9:6-15
22. Graser T, Koytchev R, Muller A, et al. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women. Climacteric 2000;3:109-18
23. Graser T, Romer T, Wiedey KD, et al. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. Climacteric 2001;4:332-42
24. Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric 2003; 6(Suppl):49-54
25. Al Azzawi F, Wahab M, Thompson J, et al. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study. Hum Reprod 1999;14:636-41
26. Al Azzawi F, Wahab M, Thompson J, et al. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric 2001;4:343-54
27. Grubb G, Spielmann D, Pickar J, et al. Clinical experience with trimegestone as a new progestin in HRT. Steroids 2003;68:921-6
28. Wahab M, Thompson J, Whitehead M, et al. The effect of a change in the dose of trimegestone on the pattern of bleeding in estrogen-treated post-menopausal women: 6 month extension of a dose-ranging study. Hum Reprod 2002;17:1386-90
29. Sidelmann JJ, Jespersen J, Andersen LF, et al. Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study. Br J Obstet Gynaecol 2003;110:541-7
30. Andersen LF, Gram J, Skouby SO, et al. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am J Obstet Gynecol 1999;180:283-9
31. Skouby SO, Gram J, Andersen LF, et al. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol 2002;186:969-77
32. Friend KE, Hartman ML, Pezzoli SS, et al. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - a clinical research center study. J Clin Endocrinol Metab 1996;81:2250-6
33. Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987;64:51-8
34. Akhrass F, Evans AT, Wang Y, et al. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J Clin Endocrinol Metab 2003; 88:5611-4
35. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72:374-81
36. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996;68:183-223
37. Campagnoli C, Biglia N, Lanza MG, et al. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. Maturitas 1994;19:25-31
38. Span JP, Pieters GF, Sweep CG, et al. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J Clin Endocrinol Metab 2000;85:1121-5
39. Isaksson E, Sahlin L, Soderqvist G, et al. Expression of sex steroid receptors and IGF-1 mRNA in breast tissue - effects of hormonal treatment. J Steroid Biochem Mol Biol 1999;70:257-62
40. Hamelers IH, Steenbergh PH. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer 2003;10:331-45
41. Hamelers IHL, van Schiak RFMA, van Teffelen HA, et al. IGF-1 action is essential for estrogen stimulated growth of MCF-7 breast tumor cells. Presented at the Denver, CO, June 2001;PI-193
42. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6
43. Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev 1995; 4:567-71
44. Catalano MG, Comba A, Fazzari A, et al. Sex steroid binding protein receptor (SBP-R) is related to a reduced proliferation rate in human breast cancer. Breast Cancer Res Treat 1997;42:227-34
45. Fazzari A, Catalano MG, Comba A, et al. The control of progesterone receptor expression in MCF-7 breast cancer cells: effects of estradiol and sex hormone-binding globulin (SHBG). Mol Cell Endocrinol 2001;172:31-6
46. Elizalde PV, Lanari C, Molinolo AA, et al. Involvement of insulin-like growth factors-I and -II and their receptors in medroxyprogesterone acetate-induced growth of mouse mammary adenocarcinomas. J Steroid Biochem Mol Biol 1998;67:305-17
47. Cline JM, Soderqvist G, von Schoultz E, et al. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996;174:93-100
48. Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-65
49. Hargreaves DF, Knox F, Swindell R, et al. Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy. Br J Cancer 1998;78:945-9
50. Dobson RR, Chan CK, Knox F, et al. The effects of prolonged HRT treatment in normal postmenopausal breast epithelium (abstract). Breast Cancer Res Treat 2000;64:106
51. Stallard S, Litherland JC, Cordiner CM, et al. Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study. Br Med J 2000;320:348-9
52. Suparto IH, Williams JK, Cline JM, et al. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys. Am J Obstet Gynecol 2003;188:1132-40
53. Cline JM, Soderqvist G, von Schoultz E, et al. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat 1998;48:221-9
54. Conner P, Soderqvist G, Skoog L, et al. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 2003;78:159-65
55. Blankenstein MA, van de Ven J, Maitimu-Smeele I, et al. Intratumoral levels of estrogens in breast cancer. J Steroid Biochem Mol Biol 1999;69:293-7
56. Pasqualini JR, Paris J, Sitruk-Ware R, et al. Progestins and breast cancer. J Steroid Biochem Mol Biol 1998;65:225-35
57. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 1999;6:75-92
58. Nabholtz JM, Bonneterre J, Buzdar A, et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003;39:1684-9
59. Smith IE. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. J Steroid Biochem Mol Biol 2003;86:289-93
60. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev 2000;21:457-87
61. Holdaway IM, Croxson MS, Ibbertson HK, et al. Cyproterone acetate as initial treatment and maintenance therapy for hirsutism. Acta Endocrinol (Copenh) 1985;109:522-9
62. van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:2-15
63. El-Etr M, Schumacher M. Effects of progesterone and related steroids in the brain. In Sitruk-Ware R, Mishell DRJ, eds. Progestins and Antiprogestins in Clinical Practice. New York: Marcel Dekker, Inc., 2000:15-58
64. Friess E, Wiedemann K, Steiger A, et al. The hypothalamic-pituitary- adrenocortical system and sleep in man. Adv Neuroimmunol 1995;5:111-25
65. Lancel M, Cronlein TA, Muller-Preuss P, et al. Pregnenolone enhances EEG delta activity during non-rapid eye movement sleep in the rat, in contrast to midazolam. Brain Res 1994;646:85-94
66. Majewska MD, Bluet-Pajot MT, Robel P, et al. Pregnenolone sulfate antagonizes barbiturate-induced hypnosis. Pharmacol Biochem Behav 1989;33:701-3
67. A-receptor modulation. Brain Res 1993;615:267-74
68. A receptor. Brain Res 1991;561:157-61
69. Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol 1995;7:171-7
70. Eriksson H, Haasio J, Korttila K. Comparison of eltanolone and thiopental in anaesthesia for termination of pregnancy. Acta Anaesthesiol Scand 1995;39:479-84
71. Brot MD, Akwa Y, Purdy RH, et al. The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors. Eur J Pharmacol 1997;325:1-7
72. Patchev VK, Shoaib M, Holsboer F, et al. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience 1994;62:265-71
73. Patchev VK, Hassan AH, Holsboer DF, et al. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacology 1996;15:533-40
74. Shifren JL. Androgen deficiency in the oophorectomized woman. Fertil Steril 2002;77(Suppl 4):S60-S62
75. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8
76. Dennerstein L, Randolph J, Taffe J, et al. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 2002;77(Suppl 4):S42-S48
77. Dennerstein L, Gotts G, Brown JB, et al. The relationship between the menstrual cycle and female sexual interest in women with PMS complaints and volunteers. Psychoneuroendocrinology 1994;19:293-304
78. Frye CA. The role of neurosteroids and nongenomic effects of progestins in the ventral tegmental area in mediating sexual receptivity of rodents. Horm Behav 2001;40:226-33
79. McEwen BS. Genomic regulation of sexual behavior. J Steroid Biochem 1988;30:179-83
80. Sinchak K, Micevych PE. Progesterone blockade of estrogen activation of mu-opioid receptors regulates reproductive behavior. J Neurosci 2001;21:5723-9
81. Davis SR. The effects of tibolone on mood and libido. Menopause 2002;9:162-70
82. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000;85:2215-22
83. Stomati M, Bersi C, Rubino S, et al. Neuroendocrine effects of different estradiol-progestin regimens in postmenopausal women. Maturitas 1997;28:127-35
84. Genazzani AR, Trentini GP, Petraglia F, et al. Estrogens modulate the circadian rhythm of hypothalamic beta-endorphin contents in female rats. Neuroendocrinology 1990;52:221-4
85. Davis SR, McCloud P, Strauss BJ, et al. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36
86. Sherwin BB. Randomized clinical trials of combined estrogen-androgen preparations: effects on sexual functioning. Fertil Steril 2002;77:S49-S54
87. Kokcu A, Cetinkaya MB, Yanik F, et al. The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas 2000;36:75-80
88. Albertazzi P, Natale V, Barbolini C, et al. The effect of tibolone versus continuous combined norethisterone acetate and oestradiol on memory, libido and mood of postmenopausal women: a pilot study. Maturitas 2000;36: 223-9
89. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003;63:463-92
90. Zimmermann T, Dietrich H, Wisser KH, et al. The efficacy and tolerability of Valette: a postmarketing surveillance study. Eur J Contracept Reprod Health Care 1999;4:155-64
91. Anderer P, Semlitsch HV, Saletu B, et al. Effects of hormone replacement therapy on perceptual and cognitive event-related potentials in menopausal insomnia. Psychoneuroendocrinology 2003;28:419-45
92. Saletu B, Anderer P, Gruber D, et al. Hormone replacement therapy and vigilance: double-blind, placebo-controlled EEG-mapping studies with an estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone in menopausal syndrome patients. Maturitas 2002;43:165-81
93. Saletu B. Östrogene und Vigilanz älterer Frauen, objectiviert mittes EEG-Mapping. In Lauritzen C, ed. Altersgynäkologie: Stuttgart: Georg Thieme Verlag, 1997:163-73
94. Saletu B. Sleep, vigilance and cognition in postmenopausal women: placebo-controlled studies with 2 mg estradiol valerate, with and without 3 mg dienogest. Climacteric 2003; 6(Suppl):37-45
95. Carlson MC, Zandi PP, Plassman BL, et al. Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study. Neurology 2001;57: 2210-6
96. Smith YR, Giordani B, Lajiness-O'Neill R, et al. Long-term estrogen replacement is associated with improved nonverbal memory and attentional measures in postmenopausal women. Fertil Steril 2001;76:1101-7
97. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 2003;289:2651-62
98. Zimmermann T, Wisser KH, Dietrich H. The effects of Valette on skin and hair: a post-marketing surveillance study. Int J Clin Pract 2000;54:85-91
99. Mueck AO, Seeger H, Ludtke R, et al. Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: estradiol versus estradiol/dienogest. Maturitas 2001;38:305-13
100. Gräser T, Koytchev R, Georgiev DB, et al. Dienogest as a progestin for hormone replacement therapy. Drugs Today 1999;35:115-26
101. Gaspard U. Pharma-clinics. Medication of the month. Totelle Cycle: new sequential estrogen/progesterone regimen for hormone replacement therapy in menopause. Rev Med Liège 2002;57:408-12
102. Wahab M, Al Azzawi F. Trimegestone: expanding therapeutic choices for the treatment of the menopause. Expert Opin Invest Drugs 2001;10:1737-44
103. Meuwissen JH, Beijers-De Bie L, Vihtamaki T, et al. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone. Gynecol Endocrinol 2001; 15:349-58
104. Elger W, Beier S, Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids 2003;68:891-905